Quality by Design approach in the development of hydrophilic interaction liquid chromatographic method for the analysis of iohexol and its impurities by Jovanović, Marko et al.
Accepted Manuscript
Title: Quality by Design approach in the development of
hydrophilic interaction liquid chromatographic method for the
analysis of iohexol and its impurities









Please cite this article as: M. Jovanovic´, T. Rakic´, A. Tumpa, B.J. Stojanovic´, Quality by
Design approach in the development of hydrophilic interaction liquid chromatographic
method for the analysis of iohexol and its impurities, Journal of Pharmaceutical and
Biomedical Analysis (2015), http://dx.doi.org/10.1016/j.jpba.2015.02.046
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.











QbD approach in HILIC method development is presented2
Analysis of iohexol and its related compounds is performed3
Monte Carlo simulation is applied for model uncertainty estimation  4
Design Space is defined5
6










Quality by Design approach in the development of hydrophilic interaction liquid 1
chromatographic method for the analysis of iohexol and its impurities2
Marko Jovanović, Tijana Rakić*, Anja Tumpa, Biljana Jančić Stojanović3
University of Belgrade – Faculty of Pharmacy, Department of Drug Analysis, Vojvode 4




*corresponding author: Tijana Rakić, University of Belgrade – Faculty of Pharmacy, Department of Drug 9















This study presents the development of hydrophilic interaction liquid chromatographic 2
method for the analysis of iohexol, its endo - isomer and three impurities following 3
Quality by Design (QbD) approach. The main objective of the method was to identify 4
the conditions where adequate separation quality in minimal analysis duration could be 5
achieved within a robust region that guarantees the stability of method performance. 6
The relationship between critical process parameters (acetonitrile content in the mobile 7
phase, pH of the water phase and ammonium acetate concentration in the water phase) 8
and critical quality attributes is created applying Design of Experiments methodology. 9
The defined mathematical models and Monte Carlo simulation are used to evaluate the 10
risk of uncertainty in models prediction and incertitude in adjusting the process 11
parameters and to identify the design space. The borders of the design space are 12
experimentally verified and confirmed that the quality of the method is preserved in this 13
region. Moreover, Plackett-Burman design is applied for experimental robustness 14
testing and method is fully validated to verify the adequacy of selected optimal 15
conditions: the analytical column ZIC HILIC (100 mm x 4.6 mm, 5 m particle size);16
mobile phase consisted of acetonitrile – water phase (72 mM ammonium acetate, pH 17
adjusted to 6.5 with glacial acetic acid) (86.7:13.3) v/v; column temperature 25 ºC, 18
mobile phase flow rate 1 mL min-1, wavelength of detection 254 nm.19
















Modern trends in pharmaceutical industry and numerous regulatory documents in this 3
field (Food and Drug Administration’s (FDA) Good Manufacturing Practice for 21st4
Century [1], International Conference of Harmonization (ICH) Q8 [2]) strongly suggest 5
the implementation of Quality by Design (QbD) concept in pharmaceutical product 6
development and consequently, in analytical method development. QbD is defined as “a 7
systematic approach to development that begins with predefined objectives and 8
emphasizes product and process understanding and process control, based on sound 9
science and quality risk management” [2]. 10
Chemometrical tools such as Design of experiments (DoE) methodology are closely 11
related to QbD and many basic concepts are very similar [3, 4]. Therefore DoE 12
methodology combined with methodologies for identification of design space provides13
deep understanding of analytical systems and enable the identification of experimental 14
region where the quality will be assured. Since liquid chromatography (LC) is the most 15
commonly applied separation technique in pharmaceutical industry, the QbD concept is16
studied in LC systems by groups of authors such as Hubert at al. [3, 5, 6], Molnar at al. 17
[7, 8], Orlandini, Furlanetto at al. [4, 9, 10]. However, the literature examination 18
revealed that there are no papers dealing with risk management and design space in 19
hydrophilic interaction liquid chromatography (HILIC). 20
HILIC has gained popularity in the analysis of polar and moderately polar analytes in 21
recent years [11]. Since certain number of drugs and their impurities are polar, HILIC 22
can represent a valuable alternative for their chromatographic separation and 23










determination. In HILIC polar or moderately polar stationary phases and polar highly-1
organic mobile phases (representing the mixtures of > 60% of organic solvent and < 2
40% of water or aqueous buffer) are used. As a result, the selectivity in HILIC 3
separation change with respect to the RP-LC separation.[12]. Bare silica columns and 4
their polar modifications (with diol, polyethylene glycol, aminopropyl, amide, 5
zwitterionic and other groups) are the columns of choice in this type of chromatography 6
[11]. 7
Zwitterionic stationary phases, which on their surface contain sulfoalkilbetaine 8
functional groups, have relatively recently found application in HILIC [11, 12]. Such 9
stationary phases possess both positive (strongly acidic sulfonic acid) and negative 10
(strongly basic quaternary ammonium groups) charge separated with short alkil spacer. 11
Since both types of charged groups are present in 1:1 molar ratio, it is reported that 12
surface net charge is zero. Sulfoalkilbetaine phases strongly adsorb water; hence the 13
retention of the analytes is driven mainly by polar interactions (hydrogen bonding and 14
dipole-dipole). Nevertheless, weak electrostatic interactions can affect the retention of 15
the analytes carrying either positive or negative charge.16
Retention mechanism of separation in HILIC is rather complex and can involve three 17
different types of processes: partitioning, surface adsorption and electrostatic interaction 18
[13 - 16]. Consequently, retention behavior and the selectivity of the chosen analytes on 19
the selected column are very often under strong influence of the factors related to the 20
mobile phase composition. Therefore, this fact can be considered an advantage when the 21
aim of the research is the optimization of chromatographic separation of the analytes’ 22
mixture.23










The incorporation of QbD strategy in HILIC method development is very important 1
since it provides better understanding of this complex type of chromatography and 2
enables dealing with optimization challenges in controlled manner. Moreover, the 3
establishment of DS in HILIC is very important since this system is generally more 4
vulnerable to slight experimental condition changes comparing to RP-LC. Therefore, 5
the aim of this study was to present the QbD method development of HILIC method for 6
the analysis of model mixture consisted of iohexol, its endo isomer and its three related 7
compounds A, B and C. Chemical structures of these analytes are presented in Figure 1. 8
Figure 19
Regarding the structures of the analytes, they can be considered neutral in the pH range 10
commonly applied in chromatographic systems. USP monograph of iohexol suggests 11
gradient RP–LC method for the quantification of iohexol and its related compounds in 12
pharmaceutical dosage forms [17]. In the literature, one paper involving the analysis of 13
iohexol and related compounds A and B in iohexol solution for parenteral 14
administration by LC–MS/MS method was found [18]. Our group has recently 15
published the work suggesting the isocratic method for the simultaneous separation and 16
quantification of iohexol and three related compounds A, B and C in iohexol solution 17
for parenteral administration on diol stationary phase in HILIC mode [19]. However, the 18
molecule of iohexol is present in two stereoisomeric forms: endo and exo, out of which 19
exo isomer is dominant [20] and the suggested HILIC method did not provide the 20
separation of endo and exo isomers of iohexol; both peaks eluted at the same retention 21
time. Simultaneous analysis of iohexol and USP related compound B in canine and 22
feline samples was also reported [20]. 23












1.1. Chemicals and reagents3
The analyzed substances iohexol and its related compounds A, B and C (obtained from 4
GE Healthcare Inc., South Central Europa) were working standards. All the reagents 5
utilized in this study were of the analytical grade. The mobile phase and the solvents 6
were prepared from acetonitrile (Lab Scan, Ireland), ammonium acetate (Verdugt b.v., 7
Netherlands), glacial acetic acid (Zorka Pharma, Serbia) and HPLC grade water. 8
OmnipaqueTM solution of iohexole for parenteral use (GE Healthcare Inc., South 9
Central Europa) was kindly donated from local distributer.10
1.2. Chromatographic conditions11
The experiments were performed on chromatographic system Finnigan Surveyor 12
Thermo Scientific consisting of HPLC Pump, Autosampler Plus and UV/VIS Plus 13
Detector. ChromQuest software was used for data collection. The analytical column14
used was ZIC HILIC (100 mm x 4.6 mm, 5 m particle size) (Merck, KGaA, Germany).15
Throughout the whole experimental procedure the following instrumental 16
chromatographic conditions were maintained: flow rate of the mobile phase 1 mL min-1,17
column temperature 25 °C, UV detection at 254 nm.18
1.3. Mobile phase19
Mobile phase consisted of acetonitrile and water phase (with added ammonium acetate20
and glacial acetic acid) where the amount of organic solvent, ammonium acetate 21
concentration in the aqueous phase and pH of the aqueous phase were varied according 22
to the experimental plan. Mobile phase under optimal chromatographic conditions was 23










as follows: acetonitrile – 72 mmol L–1 ammonium acetate in water adjusted with acetic 1
acid to pH 6.5 (86.7:13.3, v/v).2
1.4. Standard solutions3
Stock solutions for the method optimization and robustness testing contained100 μg 4
mL-1 of iohexol, and 10 μg mL-1 of all the related compounds in the mixture of 5
acetonitrile – 50 mmol L–1 ammonium acetate in water adjusted with acetic acid to pH 6
5.0 (85:15, v/v). Placebo mixture for selectivity estimation was prepared in a 7
concentration ratio corresponding to the content in the pharmaceutical dosage form 8
(solution for parenteral use). A standard solution, containing 500 μg mL–1 of iohexol 9
and 0.5 μg mL–1 of each related compound was utilized to prove the selectivity. Seven 10
solutions containing iohexol (250–750 μg mL–1) and its related compounds A, B and C 11
(0.25–0.75 μg mL–1) were prepared in the mobile phase for linearity estimation. The 12
accuracy estimation is performed using three series of three solutions containing 13
placebo, iohexol in concentrations 400 μg mL–1, 500 μg mL–1 and 600 μg mL–1 and its 14
related compounds A, B and C in concentrations 0.4 μg mL–1, 0.5 μg mL–1 and 0.6 μg 15
mL–1. The precision estimation was performed on real samples using OmnipaqueTM16
containing 350 mg of iodine per mL (approximately 755 mg of iohexol per mL). The 17
sample was diluted to contain 500 μg mL–1 of iohexol and spiked with related 18
compounds in concentration of 0.5 μg mL–1. Real samples testing was performed using 19
OmnipaqueTM diluted in the mobile phase to obtain the working solutions theoretically 20
containing 500 μg mL–1 of iohexol. This procedure was repeated six times.21
1.5. Software22
Experimental plan and data analysis according to Box-Behenken design is created in 23
DesignExpert 7.0.0. (Stat-Ease Inc., Minneapolis, MN, USA). The values of log P of the 24










analyzed compounds were estimated in MarvinSketch 6.1.0 (ChemAxon Kft., Budapest, 1
Hungary). Method optimization and Design Space definition is performed in MODDE 2
10.1 (UMETRICS, Umea, Sweden).3
2. Results and discussion4
In this paper QbD approach for development of HILIC method is presented through the 5
following phases: 1) Analytical target profile (ATP) and critical quality attributes6
(CQAs); 2) Quality risk assessment (QRA) and critical process parameters (CPPs); 3) 7
Investigation of knowledge space and Critical quality attributes modeling; 4)8
Optimization and design space; 5) Robustness testing and Method validation.9
2.1. Analytical target profile and critical quality attributes10
First objective of this work was the thorough investigation of chromatographic behavior 11
of analyzed substances. Consequently, as first set of CQAs retention factors of 12
investigated substances are selected. The second objective of the study was the 13
development of method for the analysis of iohexol and its impurities where the maximal 14
separation of substances in minimal analysis duration will be achieved. Moreover, in 15
accordance with QbD principles, the optimal conditions should be surrounded with 16
satisfactory design space in order to provide adequate robustness of the method. 17
Therefore the optimal conditions are searched as experimental point where maximal 18
selectivity factor of critical peak pair (exo and endo iohexol) in minimal analysis 19
duration and with sufficient surrounding design space could be obtained. 20
2.2. Quality risk assessment and critical process parameters21
Regarding the fact that mobile phases in HILIC usually represent aqueous- highly 22
organic mixtures containing a buffer in a certain concentration, three main CPPs 23










characterizing the mobile phase composition were identified: acetonitrile content in the 1
mobile phase, concentration of ammonium acetate in the water and pH of the water 2
phase (pH was adjusted with glacial acetic acid). 3
2.3. Investigation of knowledge space and CQA modeling4
KS presents the part of the experimental space defined by the ranges of CPPs variation.5
Analyzing the preliminary retention data, intervals of CPPs were defined (Table 1). The 6
experimental space is further on searched applying Box-Behnken design (Table 1).7
Table 18
Multiple linear regression and least squares method were applied for creation of 9
mathematical models for retention factors of the investigated substances and the results 10
are presented in Table 2.11
Table 212
Analyzing the retention behavior of investigated substances it was noted that 13
acetonitrile content in the mobile phase strongly influenced the retention of all the 14
analytes. The increase in acetonitrile content led to stronger retention of the analytes, 15
which is in accordance with theoretical knowledge of HILIC. The magnitude of the 16
influence of acetonitrile content on analytes’ retention followed the order: related 17
compound C < related compound B < related compound A < exo iohexol < endo18
iohexol. Taking into account the Log P values of iohexol and its related compounds A, 19
B and C, that were estimated to be –2.59, –1.46, –1.35 and –0.64, respectively 20
(MarvinSketch), it can be concluded that their elution order followed the pattern of the 21
increased hydrophilicity. The fact that other mobile phase factors did not have 22










statistically significant influence on the analytes’ retention suggests the absence of 1
direct interactions between the column surface and analytes. This can be for two reasons: 2
(i) the surface of sulfoakilbetaine phases strongly adsorb water within the complete 3
experimental range of factor combinations allowing the partitioning to take place, and 4
(ii) the components of the mixture were not charged molecules, therefore electrostatic 5
interactions were not likely to occur.6
After modelling of retention factors, the mathematical model for selectivity factor of 7
critical peak pair α4,5 was obtained in the following form:8
9
Selectivity factor is chosen as separation criterion since it was proved that in all the 10
experiments the peak width did not interfere with estimation of separation quality. The 11
obtained model for α4,5 was characterized by satisfactory values of relevant statistical 12
parameters. The second optimization target, minimal analysis duration, is measured by 13
the model obtained for retention factor of the last eluting peak (k5) presented in Table 2.14
In order to visualize the dependence of selected optimization CQAs on investigated 15
CPPs contour plots are constructed and presented in Supplementary files 1 and 2. 16
2.4. Optimization and Design space17
The threshold of acceptable values were defined for α4,5 (1.15) and k5 (10) in order to 18
identify the set of experimental conditions with acceptable method performances. In the 19
first phase sweet spot regions are constructed by overlay of contour plots for α4,5 and k520
and presented in Figure 2.21











However, sweet spots explain only the influence of CPPs variation on CQAs. On the 2
other hand, recent advances in pharmaceutical science highlight the implementation of 3
model uncertainty as additional source of variation of method performance [7 - 10]. In 4
case of multiobjective optimization where several responses are described by individual 5
functions, the resulting design space could be irregular and the mathematical function 6
that describes it becomes very complex. Therefore, the alternative for identification of 7
DS is the division of knowledge space into small subspaces and calculation the 8
probability of fulfilling specification within each region. In this paper DS is created 9
applying Monte Carlo simulations and obtained mathematical models using MODDE 10
10.1 software. 11
The robust optimization is performed expanding the design space around each 12
potentially satisfactory point within knowledge space and choosing the one surrounded 13
with the greatest DS. The identified point is characterized by the following CPPs 14
combination: acetonitrile content in the mobile phase 86.7%, pH value of the water 15
phase 6.5 and ammonium acetate concentration in the water phase 72 mmol L-1. The 16
resulting DS is presented in Figure 3.17
Figure 318
The obtained boarders of DS (85.2% – 88.1% for acetonitrile content in the mobile 19
phase, 4.7 – 7.8 for pH of the water phase and 49.1 – 94.8 mmol L-1 for ammonium 20
acetate concentration in the water phase) present the region where the changes of CPPs 21
will not disturb the quality of the method with the probability of 99%. The identified 22










optimal conditions and Design space boarders are verified experimentally and the 1
obtained results are presented in Figure 4 and Supplementary file 3.2
Figure 43
2.5. Robustness testing and Method validation4
Design of Experiments methodology is applied to experimentally investigate the 5
robustness of the optimum. The factors whose variation is monitored in this phase and 6
the experimental plan according to Plackett-Burman matrix are presented in 7
Supplementary file 4. In the last stage of the study the developed HILIC method is 8
validated. In Supplementary file 5 chromatograms of placebo and analyzed mixture are 9
presented. The results of the remaining validation parameters and acceptance criteria 10
[21] are summarized in Supplementary file 6. Finally, the developed method was 11
applied to real sample and the obtained results were in agreement with the declared 12
content. 13
3. Conclusion14
This study presented the usefulness of QbD approach implementation in HILIC method 15
development. The importance of this strategy in modern pharmaceutical analysis is 16
emphasized and each step of QbD process is described in details. The definition of 17
critical quality attributes and critical process parameters is explained. Special attention 18
is devoted to DoE methodology application for creation of reliable mathematical models 19
for knowledge space examination. The application of Monte Carlo simulation for 20
propagation of model uncertainty and uncertainty of process parameters adjusting is 21
used for creation of DS and robust optimization. The verification of the DS, multivariate 22










experimental robustness testing and validation confirmed that systematic building of 1
quality leads to the creation of highly reliable chromatographic methods.2
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Figure 1. The chemical structures of investigated substances3
Figure 2. Sweet spot plots obtained by plotting acetonitrile amount vs. pH of the water 4
phase at three ammonium acetate concentration in the water phase: A) 20 mM; B) 50 5
mM and C) 80 mM defined by requirements α4,5 > 1.15 and k5 < 10. Regions where 6
only one criterion is met are colored in blue, while regions where both criteria are met 7
are colored in green (to be reproduced in color on the Web (free of charge) and in black-8
and-white in print)9
Figure 3. Design space from three different perspectives A) acetonitrile content vs. pH 10
of the water phase, while ammonium acetate concentration is 72 mM; B) acetonitrile 11
content vs. ammonium acetate concentration while pH of the water phase is 6.5; C) pH 12
of the water phase vs. ammonium acetate concentration while acetonitrile content is 13
86.7% (to be reproduced in color on the Web (free of charge) and in black-and-white in 14
print)15
Figure 4. The experimentally obtained chromatogram under the optimal conditions16
17
Figure caption for supplementary files18
Supplementary 1. Contour plots for k5 obtained by plotting acetonitrile amount vs. pH 19
of the water phase at three ammonium acetate concentration in the water phase: A) 20 20
mM; B) 50 mM and C) 80 mM21










Supplementary 2. Contour plots for α4,5 obtained by plotting acetonitrile amount vs. 1
pH of the water phase at three ammonium acetate concentration in the water phase: A) 2
20 mM; B) 50 mM and C) 80 mM3
Supplementary 5. Representative chromatograms of A) placebo mixture and B) 4
laboratory mixture for precision testing. Peak annotation: 1 - related substance C; 2 –5
related substance B; 3 – related substance A; 4 – exo iohexol; 5 – endo iohexol6
7











Table 1. Plan of experiments and the obtained retention data2
3
x1 –acetonitrile content in the mobile phase (%);x2 – pH of the water phase; x3 –4
ammonium acetate concentration in the water phase (mmol L-1); k1– retention time of 5
related compound C; k2– retention time of related compound B; k3– retention time of 6
related compound A; k4– retention time of exo iohexol; k5– retention time of endo7
iohexol.8
9
x1 x2 x3 k1 k2 k3 k4 k5
1 80 3.0 50 0.11 0.41 0.71 1.11 1.39
2 90 3.0 50 1.45 3.28 6.16 12.04 15.31
3 80 7.0 50 0.10 0.38 0.66 1.03 1.29
4 90 7.0 50 1.30 2.86 5.41 10.31 13.13
5 80 5.0 20 0.08 0.35 0.61 0.96 1.20
6 90 5.0 20 1.26 2.80 5.20 9.95 12.51
7 80 5.0 80 0.11 0.40 0.71 1.12 1.40
8 90 5.0 80 1.35 2.90 5.62 10.66 13.73
9 85 3.0 20 0.36 0.93 1.58 2.63 3.27
10 85 7.0 20 0.37 0.89 1.53 2.55 3.17
11 85 3.0 80 0.44 1.04 1.83 3.05 3.84
12 85 7.0 80 0.42 0.96 1.70 2.81 3.53
13 85 5.0 50 0.38 0.92 1.61 2.66 3.34
14 85 5.0 50 0.39 0.91 1.61 2.67 3.35
15 85 5.0 50 0.40 0.92 1.62 2.68 3.18










Table 2. Coefficients of the obtained second-order polynomial retention models in 1
terms of coded factor values and statistical analysis2





k1– retention time of related compound C; k2– retention time of related compound B; k3–5
retention time of related compound A; k4– retention time of exo iohexol; k5– retention time of 6
endo iohexol7
* Coefficients significant for p-value < 0.058
9
k1 k2 k3 k4 k5
coefficient p–value coefficient p–value coefficient p–value coefficient p–value coefficient p
0.390 <0.0001* 0.920 <0.0001* 1.610 <0.0001* 2.670 <0.0001* 3.290 <0.0001*
0.620 <0.0001* 1.290 <0.0001* 2.460 <0.0001* 4.840 <0.0001* 6.180 <0.0001*
–0.020 0.1117 –0.071 0.0578 –0.120 0.0676 –0.270 0.0878 –0.340
0.034 0.0235* 0.043 0.1984 0.120 0.0771 0.190 0.1862 0.290
–0.034 0.0686 –0.094 0.0707 –0.180 0.0657 –0.410 0.0683 –0.520
0.016 0.3200 0.014 0.7523 0.079 0.3380 0.140 0.4669 0.260
–0.007 0.6531 –0.011 0.7986 –0.021 0.7907 –0.041 0.8282 –0.051
0.320 <0.0001* 0.740 <0.0001* 1.490 <0.0001* 3.180 <0.0001* 4.120 <0.0001*
0.024 0.1814 0.080 0.1199 0.120 0.1729 0.270 0.2056 0.370
–0.013 0.4317 0.042 0.3682 –0.075 0.3785 –0.180 0.3748 –0.200
0.9988 0.9978 0.9980 0.9972 0.9972
0.9965 0.9938 0.9945 0.9922 0.9921
2 0.9804 0.9648 0.9688 0.9557 0.9556
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